VIVOS INC
Raising nowPublicHealthcare · Richland, WA
Vivos develops RadioGel, an injectable yttrium-90 gel for radiation treatment of tumors that can't be surgically removed, targeting papillary thyroid cancer in people. It already sells the same device as IsoPet to veterinarians for animal tumors and certifies vet clinics. The FDA granted RadioGel Breakthrough Device designation, and human trials are being pursued in India.
This company has an open fundraising round.
Financials
FY2010–FY2025 · from SEC filings · hover any figure for its sourceChart shows the most recent 8 fiscal years; 8 earlier years are in the table below.
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inDotted grey bars are our estimate for rounds that didn't state one: the round's share price × the shares outstanding in its filings. Same measure as blue, but rougher.
Share price over rounds
Disclosed sales come from the issuer's own filings (prior-offering lines, audited-statement notes) and are amount ÷ securities sold. A down round is a firm point more than 25 % below the previous firm point of the same share class on a comparable basis; the comparison ignores unverified and year-only lines.
Cap table
Share counts as of Mar 4, 2026| Class | Outstanding | Votes / share | Converts | As converted | Last price |
|---|---|---|---|---|---|
| Series A Convertible Preferred Stockpreferred | 2,071,007 | — | 1.25 × Common Stock | 0.57% | — |
| Common Stock | 455,538,356 | 1 | — | 99.4% | $0.08Mar 2026 |
| Total | 457,609,363 | 458,127,114.75 as converted | 100% |
Shares outstanding over timein today's share terms
Changes in named holdersshares in today's terms · % of all shares at the time
- L. Bruce Jolliff920 Mar 2010 → 2K Mar 2012 → 3K Mar 2013 → 3K Mar 2014 → 3K Apr 2015 → 38K Jan 2018 → 292K Apr 2018 → 12K (0.24%) Mar 2019 → 198K (4.03%) Jul 2019
- Stoel Rives8K (0.16%) Mar 2019 → 133K (2.71%) Jul 2019
- Firstfire Global Opportunities Fund12K (0.24%) Mar 2019 → 114K (3.8%) Feb 2021 → 363 (0.02%) Mar 2025
- Michael Pollack16K (0.53%) Feb 2021 → 25M (953.0%) Oct 2023 → 16K Mar 2024 → 30M (1464.0%) Feb 2026 → 31M (1490.5%) Mar 2026
- Carlton M. Cadwell25K Mar 2012 → 31K Mar 2013 → 41K Mar 2014 → 325K Apr 2015 → 33K May 2016 → 75K Jan 2018 → 548K Apr 2018 → 54K (1.1%) Mar 2019 → 909K (18.5%) Jul 2019 → 385K (13.3%) Sep 2021
- Michael K. Korenko400K Apr 2018 → 5.3M (107.7%) Mar 2019 → 11M (230.4%) Jul 2019 → 14M (283.8%) Sep 2019 → 14M (7.45%) Oct 2019 → 31M (625.7%) Nov 2019 → 37M (823.5%) Apr 2020 → 34M (1140.7%) Feb 2021 → 10M (348.9%) Sep 2021 → 25M (936.7%) Mar 2023 → 9.9M (372.1%) Oct 2023 → 15M Mar 2024 → 15M (745.3%) Mar 2025
- Cadwell Family Irrevocable Trust13K Mar 2012 → 10K Jan 2018 → 101K Apr 2018 → 212K (4.32%) Jul 2019 → 27K (0.6%) Apr 2020 → 148K (5.13%) Sep 2021
- Major Shareholder43K Apr 2018 → 8K (0.16%) Mar 2019 → 130K (2.64%) Jul 2019 → 382K (8.51%) Apr 2020 → 198K (6.61%) Feb 2021 → 114K (3.8%) Mar 2021 → 198K (6.84%) Mar 2022
- Jason Adelman26K (0.53%) Mar 2019 → 436K (15.1%) Sep 2021 → 200K (6.91%) Mar 2022
- DiamondRock LLC12K (0.25%) Mar 2019 → 210K (4.27%) Jul 2019 → 100K (2.03%) Nov 2019
- MEF I, LP15K Apr 2018 → 252K (5.12%) Jul 2019
- Cipher897K (18.2%) Jul 2019 → 577K (11.7%) Nov 2019
- Thomas J. Clement148 Mar 2013 → 223 Mar 2014 → 3K May 2016 → 6K Jan 2018
- James C. Katzaroff4K Mar 2010 → 4K Mar 2011 → 5K Mar 2012 → 4K Mar 2013 → 4K Mar 2014 → 5K Apr 2015 → 4K May 2016 → 84K Jan 2018
- Carlton Cadwell14K Mar 2010 → 18K Mar 2011
Principal holders% as the filing states it, Mar 31, 2026
- Stockholders: Firstfire Global Opportunities Fund363 shares100.0%of company
- Carlton M. Cadwell385,302 Series C Convertible Preferred Stock100.0%of Series C Convertible Preferred
- Firstfire Global Opportunities Fund363 Series B Convertible Preferred Stock100.0%of Series B Convertible Preferred
- Carlton M. Cadwell1,057,219 Series A Convertible Preferred Stock51.0%of Series A Convertible Preferred
- Stockholders: L. Bruce Jolliff197,979 shares9.56%of company
- L. Bruce Jolliff197,979 Series A Convertible Preferred Stock9.56%of Series A Convertible Preferred
- Stoel Rives133,333 Series A Convertible Preferred Stock6.44%of Series A Convertible Preferred
- Michael Pollack30,868,981 shares6%of company
- Michael K. Korenko15,435,090 Common Stock3%of
- Carlton M. Cadwell15,433,891 Common Stock3%of
- Brad Weeks15,433,891 shares3%of company
Sold to the crowd
- Reg A+ · Sep 202118,112,380 Common Stock at $0.10$1.8M
From the company's SEC filings: share counts per class, each class's voting and conversion terms, and the holders of 20% or more that Form C requires (officers and 10%+ holders on Form 1-A). Filings name only large holders, so most owners — including crowd investors — are not listed, and a holder's percentage may be of its own class rather than of the whole company. “As converted” counts each class in the shares it converts into. Prices and crowd share counts are in today's share terms — adjusted for splits and conversions since they were sold. Hover a figure for its filing.
Fundraising history
Team
5 peopleNames and titles as disclosed on SEC Form 1-A. Bios and photos come from the platform campaign page and may be out of date.
SEC filings
View all 118 filings on EDGAR- Form 10-QAug 12, 20260001493152-26-037380EDGAR
- Form 10-QMay 14, 20260001493152-26-023146EDGAR
- Form 10-KMar 31, 20260001493152-26-013701EDGAR
- Form QUALIFMar 5, 20269999999994-26-000052EDGAR
- Form 1-A/AMar 4, 20260001493152-26-008813EDGAR
- Form 1-AFeb 17, 20260001493152-26-006865EDGAR
- Form 10-QNov 12, 20250001493152-25-021619EDGAR
- Form 10-QAug 13, 20250001641172-25-023437EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.